Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly encompassed under nonalcoholic fatty liver disease (NAFLD), is a growing global health burden associated with progression to cirrhosis and hepatocellular carcinoma. Resmetirom, a thyroid hormone receptor-β (THR-β) agonist, and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), have emerged as promising agents targeting distinct metabolic and inflammatory pathways. This systematic review compares the safety and efficacy of resmetirom and semaglutide in MASLD. Methods: We conducted a comprehensive search of PubMed, Embase, and Google Scholar for randomized controlled trials and clinical studies published between January 2014 and April 2025, following PRISMA guidelines. Studies assessing the efficacy and safety of resmetirom and/or semaglutide in MASLD or NASH were included. Data extraction was performed by two independent reviewers, and a narrative synthesis was undertaken due to the heterogeneity in study design and outcome measures. Results: Fourteen studies encompassing over 4500 patients were analyzed. Resmetirom demonstrated consistent reductions in hepatic fat (≥30% in >50% of patients) and improvements in fibrosis (≥1 stage in up to 26.4% of patients), as evidenced in the MAESTRO-NASH trial. Semaglutide achieved higher rates of NASH resolution (up to 62.9%) without worsening fibrosis, especially among patients with type 2 diabetes or obesity, although fibrosis improvement was less consistently observed. Resmetirom was well tolerated with low discontinuation rates, while semaglutide was associated with more frequent, yet manageable, gastrointestinal adverse events. Conclusions: Both resmetirom and semaglutide show therapeutic potential for MASLD. Resmetirom offers more consistent antifibrotic effects, while semaglutide excels in NASH resolution and metabolic improvement. The absence of direct comparative trials underscores the need for future head-to-head studies to guide tailored treatment strategies in MASLD management.
27 September 2025 in Digestive Diseases and Sciences
Hemospray (TC-325), a powder-based hemostatic spray, is increasingly used for upper gastrointestinal bleeding but can rarely cause endoscope retention. A 74-year-old woman with chronic kidney disease, atrial fibrillation on warfarin, mechanical heart valves, and prior gastric ulcers presented with melena and large-volume hematemesis causing hemodynamic instability. Laboratory findings revealed hemoglobin 7.3 g/dL and international normalized ratio 7. Esophagogastroduodenoscopy showed multiple bleeding arteriovenous malformations in the cardia and fundus, treated with a synthetic self-assembling peptide gel and subsequently with hemospray applied in retroflexion. Withdrawal of the endoscope was initially unsuccessful due to powder adhesion, but aggressive water irrigation enabled removal after 90 minutes. The patient stabilized with transfusions and octreotide, with no recurrent bleeding. This case underscores the risk of endoscope retention when Hemospray is applied retroflexed and suggests aggressive irrigation as a potential remedy. Further studies are needed to optimize Hemospray dosing and evaluate self-assembling peptide-powder interactions.